header image

Immunotherapy

Immunotherapy is not merely a drug or class of drugs, but rather a therapeutic principle that aims to treat immune-mediated diseases and deficiencies by inducing, enhancing, or suppressing an immune response through immunomodulation or immunoglobulin replacement therapy. These products form the lifeline to health and hope for countless patients and their families around the globe. Our long-term commitment to patients requiring immunoglobulin is demonstrated by our unique portfolio, which offers different concentrations and routes of administration in liquid ready-to-use solutions.

 

 

Immune Globulin Intravenous (Human) 5% Liquid Preparation

 

Octagam is an immune globulin intravenous (human) 5% liquid indicated for treatment of primary humoral immunodeficiency (PI), such as congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome and severe combined immunodeficiencies.

 

Octagam® 5% Prescribing Information

Octagam® 5% Website

 

 

Immune Globulin Intravenous (Human) 10% Liquid Preparation

 

Octagam 10% is indicated in Chronic Immune Thrombocytopenic Purpura to rapidly raise platelet counts to control or prevent bleeding in adults.

 

Octagam® 10% Prescribing Information

Octagam® 10% Website

 WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE

Please see full prescribing information for complete boxed warning. 

 

  • Thrombosis may occur with immune globulin intravenous (IGIV) products, including Octagam 5% and Octagam 10%. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.


  • Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of immune globulin intravenous (human) (IGIV) products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Octagam 5% and Octagam 10% do not contain sucrose.


  • For patients at risk of thrombosis, renal dysfunction or renal failure, administer Octagam 5% and Octagam 10% at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.